Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-349P (RNA, U6 small nuclear 349, pseudogene) is a **transcribed pseudogene** derived from the U6 small nuclear RNA (snRNA) gene family. U6 snRNA itself is a well-conserved, functional non-coding RNA critical for pre-mRNA splicing as part of the spliceosome[3][1]. However, pseudogenes such as RNU6-349P are **non-functional copies** or fragments of ancestral genes that lack protein-coding potential. Many U6-derived pseudogenes exist in the human genome as a result of the evolutionary significance of U6 snRNA, but these pseudogenes generally do not produce functional RNA molecules and are not known to directly participate in splicing[2][3]. Some pseudogenes are transcribed into non-coding RNAs that may act as regulators of gene expression, often through competitive RNA mechanisms (such as acting as miRNA “sponges” or generating small RNAs with potential effects on chromatin structure or mRNA stability)[2]. There is no evidence that RNU6-349P serves as a direct therapeutic or diagnostic target, nor does it have known drug interactions or established safety concerns. In general, U6 pseudogenes are classified as **non-coding RNA pseudogenes** and are studied primarily for their potential roles in gene regulation rather than as actionable molecular targets[2][3]. **Note:** - RNU6-349P is not a receptor, enzyme, transporter, or canonical therapeutic target. - As a pseudogene, its functional significance (if any) would likely be regulatory and indirect, and there are no established disease or drug relationships specific to RNU6-349P[2]. - There is nothing fundamentally “incorrect” about this target as described; however, its status as a pseudogene means it is not a typical drug or receptor target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 349, pseudogene (RNU6-349P).